Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Inclusion Criteria: * Patients are ≥ 18 years old * Capacity to understand and willingness to provide written informed consent * Diagnosis or clinical suspicion of recurrent malignant glioma, including: * History of high-grade glioma (World Health Organization \[WHO\] grade III or IV), or * Prior, histologically-confirmed diagnosis of grade II glioma with new radiographic findings consistent with a high-grade glioma * Imaging and/or histopathological confirmation of recurrent disease, or verification of "high risk" histology confirmed by a biopsy with measurable disease by the Radiologic Assessment in Neuro-Oncology (RANO) criteria * Patient has unifocal disease in one hemisphere and is supratentorial. Lesion and edema can not be located in eloquent locations (e.g., brainstem, pre-/post-central gyrus, visual cortex) or within 2 gyri of motor strip. * If on steroids such as dexamethasone, must be on a low dose (≤ 4mg per day) at the time of treatment, and not at an ascending dosage schedule at time of enrollment/leukapheresis * Prior to apheresis and treatment 1 a 2- week washout should be observed * Subjects must not have received bevacizumab therapy and are not planned to start such therapy * Karnofsky performance score (KPS) ≥ 60 * Subject is a surgical candidate for surgery for malignant glioma with the intent of resecting \>80-90% of the tumor as the ideal treatment option * White blood cells (WBC) \> 4,000 cells/uL * Hemoglobin (Hgb) \> 7 gm/dL * Platelets (Plt)…